Skip to main content

Protein based covid-19 vaccine

 

A protein-based COVID-19 vaccine that mimics the shape of the virus


Posted Today

Even as several safe and effective COVID-19 vaccines are being administered to people worldwide, scientists are still hard at work developing different vaccine strategies that could provide even stronger or longer-lasting immunity against SARS-CoV-2 and its variants.


Now, researchers reporting in ACS Central Science have immunized mice with nanoparticles that mimic SARS-CoV-2 by displaying multiple copies of the receptor binding domain (RBD) antigen, showing that the vaccine triggers robust antibody and T cell responses.



Although the first vaccines to receive Emergency Use Authorization by the U.S. Food and Drug Administration were based on mRNA, more conventional protein-based vaccines have also shown promise in clinical trials. Most train the immune system to recognize the RBD, a peptide that is the portion of the SARS-CoV-2 spike protein that binds to the ACE-2 receptor on host cell surfaces.


However, not all of these vaccines elicit both antibody and T cell responses, both of which are thought to be important for longer-lasting immunity. Melody Swartz, Jeffrey Hubbell and colleagues had previously developed a vaccine delivery tool called polymersomes –– self-assembling, spherical nanoparticles that can encapsulate antigens and adjuvants (helper molecules that boost the immune response) and then release them inside immune cells. Polymersomes trigger robust T cell immunity, and the researchers wondered if they could further improve the antibody response by engineering the nanoparticles to mimic viruses by displaying multiple copies of the RBD on their surfaces.


So the team made polymersomes that were similar in size to SARS-CoV-2 and decorated them with many RBDs. After characterizing the nanoparticles in vitro, they injected them into mice, along with separate polymersomes containing an adjuvant, in two doses that were three weeks apart. For comparison, they immunized another group of mice with polymersomes that encapsulated the RBD, along with the nanoparticles containing the adjuvant. Although both groups of mice produced high levels of RBD-specific antibodies, only the surface-decorated polymersomes generated neutralizing antibodies that prevented SARS-CoV-2 infection in cells.

Both the surface-decorated and encapsulated RBDs triggered robust T cell responses. Although the new vaccine still needs to be tested for safety and efficacy in humans, it could have advantages over mRNA vaccines with regard to widespread distribution in resource-limited areas, the researchers say. That’s because the surface-decorated polymersomes are stable and active for at least 6 months with refrigeration, in contrast to mRNA vaccines that require subzero temperature storage.



Comments

Post a Comment

Popular posts from this blog

The Present And Future Of Corona Virus Variants

 Future of covid19 Recently, the Centers for Disease Control and Prevention confirmed what Harvard-affiliated physicians had reported from anecdotal and laboratory evidence: the delta variant of COVID-19 not only spreads more rapidly than other versions of the virus, it can sicken vaccinated individuals who can then spread the virus to others. In its “Morbidity and Mortality Weekly Report,” the CDC revealed that 75 percent of patients in a cluster of 469 cases in Provincetown, Massachusetts, were vaccinated, a sobering statistic for Americans who only weeks ago were optimistic that the pandemic’s end was in sight. Coronavirus. Credit: Pete Linforth on Pixabay, free licence “New scientific data shows that delta behaves differently than other variants,” CDC Director Rochelle Walensky said in a briefing last Wednesday. “On rare occasions, some vaccinated people may be contagious and spread the virus to others.” Many of these patients shrug off initial symptoms, Poznansky said, attributing
Post a Comment
Read more

Uranium isotopes helps defending atomic material

  Fast identification of uranium isotopes helps defend atomic materials Scientific physicists at the Division of Energy's Oak Edge Public Research center have fostered a fast way of estimating isotopic proportions of uranium and plutonium gathered on natural swipes, which could help Global Nuclear Energy Organization investigators identify the presence of undeclared atomic exercises or material.  "This strategy expands on a business microextraction test to straightforwardly test solids and thusly remove the analytes from a surface and into a streaming arrangement," said ORNL's Benjamin Manard. He drove the confirmation of-idea study, which exhibited that this inspecting system was compelling at extricating actinide material (e.g., uranium and plutonium) from ecological swipes. The paper made the title page of the diary Logical Science.  ORNL logical physicists coupled a microextraction test to a mass spectrometer for estimation of uranium isotope proportions from natu
Post a Comment
Read more

First Corona Virus Immunization

 FDA Endorses First Coronavirus Immunization  Today, the U.S. Food and Medication Organization endorsed the main Coronavirus antibody. The immunization has been known as the Pfizer-BioNTech Coronavirus Antibody, and will presently be advertised as Comirnaty (koe-mir'- na-tee), for the avoidance of Coronavirus sickness in people 16 years old and more seasoned. The immunization additionally keeps on being accessible under crisis use approval (EUA), including for people 12 through 15 years old and for the organization of a third portion in certain immunocompromised people.  a vial with Coronavirus antibody  "The FDA's endorsement of this antibody is an achievement as we keep on fighting the Coronavirus pandemic. While this and different antibodies have met the FDA's thorough, logical guidelines for crisis use approval, as the principal FDA-endorsed Coronavirus immunization, people in general can be extremely certain that this antibody fulfills the high guidelines for well
Post a Comment
Read more